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Adoptive cell transfer (ACT) using in vitro expanded T
cells from biopsy material represents a highly promising
treatment of disseminated cancer. ACT in its present form
is rather crude and improvements seem within reach.
Recruitment of transferred lymphocytes to the tumor site
is a crucial step in ACT efficacy; however, quite few T cells
actually reach the tumor site upon administration. In the
present pre-clinical study we have genetically engineered T
cells aiming at increasing the homing of T cells by match-
ing expression of chemokine receptors on T cells to che-
mokines secreted by the tumor, thus improving anti-tumor
efficacy of ACT. By PCR analysis we found that several
malignant melanoma (MM) cell lines showed expression of
cytokines CXCL8/IL-8, CXCL12/SDF-1 and CCL2, which
was confirmed by ELISA analysis of MM conditioned med-
ium. Taking advantage of mRNA electroporation we suc-
cessfully transfected T cells with mRNA encoding the
chemokine receptors CXCR2 or chimeric receptor
CXCR4-R2 on the cell surface, of which the chimeric con-
structs contain the intracellular region of CXCR2 achieving
a significant increase in cell surface expression on the T
cell. Both the wildtype and chimeric chemokine receptors
are functional in vitro and show an increase in Ca2+ influx
upon binding and mediate specific migration of receptor
transfected T cells towards CXCL8 and CXCL12 respec-
tively, as well as towards MM conditioned medium. Migra-
tion towards conditioned medium was abolished by the
addition of neutralizing antibodies against the respective
ligands. Using the NOG mouse model for xenograft assess-
ment of migration in vivo of receptor transfected T cells
showed that CXCR2 transfected T cells possess a slightly
increased tumor infiltration compared to mock transfected,
which seem to be “stuck” in the lungs. In conclusion, both
our CXCR2 and CXCR4-R2 chimeric receptor is functional
in vitro, and transfection with CXCR2 seemed to increase
the homing of CXCR2 transfected cells to the tumor site,
thus setting the stage for future clinical application.
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